| News
University of Basel and RocketVax present new Covid vaccine
22.05.2023
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech startup RocketVax. It is based on a modified version of the virus that can no longer replicate. The vaccine can be produced cost-effectively and is simple to store and administer.

Covid vaccine research in the laboratory (image: University of Basel)
The University of Basel and RocketVax, a biotechnology startup also based in Basel, are focusing on a new principle, namely single-cycle viruses, in the development of a new vaccine. According to a press release, the vaccine can simply be stored in a refrigerator. It is administered by nasal drop, which does not require trained medical personnel. In addition, the production method for the vaccine is said to be particularly cost-effective and can be easily adapted to future virus variants.
The vaccine is based on a modified version of the coronavirus produced in a lab setting. However, it is unable to replicate further after entering the human body. “Among other things, we remove a specific gene from the blueprint for the viral envelope”, as study leader Prof. Dr. Thomas Klimkait from the Department of Biomedicine at the University of Basel explains in the press release, adding that: “If this envelope component is missing, no new virus particles can be formed”.
Broad financial support
However, the individual virus components are still produced. The body cells present these on their surface to the immune system, which recognizes the virus building blocks and builds up effective immune protection. The team also removed genes that the virus uses to inhibit the immune response of the cells. A patent application for the concept has now also been submitted by the researchers.
RocketVax collaborated on the development and preclinical studies. For the successful animal experiments with hamsters, the team cooperated with the Friedrich Loeffler Institute in Germany. The partnership is embedded in a research cooperation with University Hospital of Basel and the Swiss Tropical and Public Health Institute (Swiss TPH). The University Hospital of Basel and the Canton of Basel-Stadt provided startup funding for the preclinical research activities in connection with the new vaccine, which were already underway. The project also received financial support from Innosuisse, the Swiss innovation agency.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Artificial Intelligence – the Holy Grail to Healthcare Innovation?
Last winter, Julia got a cough and a headache. For the third time she went to her physician, who sent...
Read MoreBaselArea.swiss Presents the DayOne Acceleration Program Supported by Fondation Botnar
Seeking brilliant project ideas that, combined with digital technologies, healthcare expertise and entrepreneurial spirit, will help solve the health challenges...
Read MoreInvesting in strengths – Swiss leadership in life sciences
How can Switzerland and the Basel region maintain their international leadership role in life sciences? As part of the Biotech...
Read MoreBaseLaunch can take full advantage of the potential of Basel’s life sciences ecosystem
The new accelerator for healthcare ventures, BaseLaunch, wants to link the best start-ups to the Basel region – and in...
Read MoreBasel impresses with quality of living
Basel is among the top ten cities with the highest quality of living in the world, according to the latest...
Read More“Muttenz is home to the world’s largest plant for the production of 5-HMF from biomass”
Thomas Fischer is Chief Operating Officer with the biotechnology company AVA Biochem in Muttenz.
Read More